7 results about "Bronchitis" patented technology

The present application relates to a kind of traditional Chinese medicine composition for treating acute exacerbation of chronic bronchitis, the traditional Chinese medicine composition is made of the following weight parts of raw medicinal materials: 10-14 parts of pinellia ternata, 7-11 parts of apricot kernel, 7-11 parts of persicae semen, 7-11 parts of dried tangerine or orange peel, 10-14 parts of radix codonopsis, 13-17 parts of oyster shell, 13-17 parts of concha mactrae, 13-17 parts of ophiopogon japonicus, 7-11 parts of radix clematidis, 1-5 parts of soap plant thorn.The present application is mainly used for treating syndrome of phlegm-dampness accumulating in lung;Effect: dry dampness and resolve phlegm, regulate qi and relieve cough;The monarch drug pinellia ternata in the present application is pungent, flat, warm and dry, and is good at dry dampness and resolve phlegm, and can descend adverse qi and relieve panting.Peach kernel and apricot kernel are used as ministers, which is a wonderful use of qi-blood confrontation: peach kernel enters blood and regulates qi, and apricot kernel enters qi and regulates blood, and the two are complementary, helping pinellia ternata to rotate qi and restore ascending and descending. The use of auxiliary drugs has three meanings: one is to attack evil, radix clematidis can pass through twelve meridians and remove phlegm, soap plant thorn is sharp and can break and soften, and is good at attacking stubborn phlegm. The combination of various drugs can attack and tonify, and is suitable for moistening dryness, and can achieve the effect of dry dampness and resolve phlegm, regulate qi and relieve cough.

The present invention provides an antibody or a conjugated fragment of a citrulline-containing epitope used for the treatment or prevention of diseases associated with the release of extracellular traps from cells, such as neutrophil extracellular trap (NET)-associated pathology (NET-associated pathology) or eosinophil extracellular trap (EET)-associated pathology (EET-associated pathology), and provides a method comprising administering at least one dose of the antibody at a specific concentration. The present invention also provides the method itself. NET-related pathologies include systemic lupus erythematosus (SLE), lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus exacerbated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, or wound healing in diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in This includes other NET-related pathologies, such as the health of transplanted organs in vivo or ex vivo.The present invention also relates to wound healing in SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid antibody syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia asthma, allergic rhinovirus exacerbating asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, thrombotic disease, cardiovascular disease, or diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in vivo or ex vivo The present invention provides pharmaceutical compositions and methods for treating and preventing NET-related pathologies, including other NET-related pathologies such as the health of transplanted organs in vivo. NET-related pathologies include eosinophilic diseases or conditions of the skin, respiratory eosinophilic diseases or conditions, gastrointestinal eosinophilic diseases or conditions, allergic diseases or conditions, or eosinophilic diseases or conditions such as helminthic, fungal, viral or bacterial infections.

The present invention relates to a compound of formula (I) wherein R1 and R2 are as defined herein, a pharmaceutical composition comprising such compound for treatment of a PGD2-mediated disorder including, to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which are generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like.

This disclosure relates to RNA molecules encoding respiratory syncytial virus (RSV). This disclosure further relates to compositions comprising RNA molecules formulated in lipid nanoparticles (RNA-LNPs). This disclosure further relates to the use of RNA molecules, RNA-LNPs, and compositions for the treatment and / or prevention of RSV infection-induced acute respiratory tract diseases, including pneumonia and bronchitis.

The present invention relates to oligosaccharide preparations for treating, alleviating, preventing, and / or delaying respiratory diseases, preferably infectious bronchitis, and / or their effects.

This invention relates to a traditional Chinese medicine composition for treating spasmodic cough in children. The composition is made from the following raw materials in parts by weight: honeysuckle 10-14 parts, earthworm 7-11 parts, cicada slough 4-8 parts, belamcanda chinensis 7-11 parts, scutellaria baicalensis 7-11 parts, honey-processed coltsfoot flower 7-11 parts, lily bulb 7-11 parts, ginger-processed bamboo shavings 7-11 parts, and licorice root 1-5 parts. This invention also provides the application of this traditional Chinese medicine composition in the preparation of a drug for treating spasmodic cough in children. In this formula, honeysuckle and earthworm are the principal herbs; cicada slough, scutellaria baicalensis, and belamcanda chinensis are the assistant herbs; ginger-processed bamboo shavings, coltsfoot flower, and lily bulb are the adjuvant herbs; and licorice root is the guiding herb. This formula treats cough with phlegm belonging to the wind-cold transforming into heat type. This invention promotes lung function, eliminates phlegm, relieves spasms, and stops cough. Main indications: spasmodic cough caused by pertussis, bronchitis, asthma, etc.